SARS-CoV-2-antibodies may promote severe COVID-19
Immunoglobin G antibodies (IgG) produced in response to the SARS-CoV-2 spike protein appear to play a role in how COVID-19 can turn more severe in some cases.
ADVERTISEMENT
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 2082 entries already.
Entries by Thomas Gabrielczyk
Abingworth raises $582m for late-stage fund ACCD 2
International life sciences investment group Abingworth has closed a new clinical co-development fund at US$582m.
USA supports to temporarily waive IP of COVID-19 vaccines
The Biden administration has announced it will support the WHO proposal to temporarily waive intellectual property rights for COVID-19 vaccines to speed up vaccination.
Swiss Oculis SA raises $57m in Series C
Topical ophthalmic therapies developer Oculis S.A. has closed a US$57m Series C financing to push development of its pipeline.
Mogrifiy completes Series A financing round
Cell reprogramming specialist Mogrify Ltd has announced the second closing of its Series A financing of $17m, bringing the total raised to $33m in this round.
COVID-19 vaccine for poor countries
Moderna Inc. has signed a COVID-19 vaccine supply agreement with vaccination alliance Gavi.
Increase viral RNA extraction throughput with automation
During the global COVID-19 outbreak, BioEcho developed a rapid extraction protocol that reduced the isolation of SARS-CoV-2-RNA to just a few minutes. Currently, BioEcho offers a CE-marked viral RNA/DNA extraction kit and is implementing automated solutions that will allow customers to increase their diagnostics throughput.
ADCendo ApS raises €51m in Series A financing
Danish ADCendo ApS will use the funds from a Series A investment to advance Antibody-Drug Conjugates (ADCs) entering cancer cells through endocytic receptors.
DNA Script bags DARPA funding
DNA Script will receive a $5m DARPA grant as part of the agency’s Nucleic Acids On-Demand World-Wide Program to prevent the next viral pandemic.
First malaria vaccine meets WHO efficacy criteria
Researchers at Novavax and from the University of Oxford reported an efficacy of 77% of their malaria vaccine, R21/Matrix-M from a Phase II trials in Burkina Faso.